CSIMarket
 


Marinus Pharmaceuticals Inc   (MRNS)
Other Ticker:  
 

Cumulative Marinus Pharmaceuticals Inc 's Working Capital Ratio for Trailing Twelve Months Period

MRNS's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

MRNS Working Capital Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Growth 36.12 % 4.05 % 3.36 % 29.4 % 32.82 %
Y / Y Current Assets Growth 10.19 % 92.51 % 62.87 % 91.66 % 15.32 %
Working Capital Ratio for Trailing Twelve Months Period 8.8 9.35 8.4 7.5 6.56
Total Ranking # 349 # 354 # 452 # 614 # 931
Seq. Current Liabilities Growth 19.16 % 19.09 % -19.28 % 18.85 % -8.91 %
Seq. Current Assets Growth 0.22 % -11.54 % -12.83 % 42.58 % 75.1 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Due to increase in Current Liabilities in the III. Quarter to $29 millions, average cumulative Working Capital Ratio for Trailing Twelve Months Period decreased to 8.8 below Marinus Pharmaceuticals Inc average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 182 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Marinus Pharmaceuticals Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about MRNS
Working Capital Ratio MRNS in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 183
Sector # 309
S&P 500 # 475


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
19.27 9.24 4.31
(Jun 30 2018)   (Jun 30 2022)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Rezolute Inc   24.17 
Cyteir Therapeutics Inc   24.12 
Eqrx Inc   24.02 
Astria Therapeutics inc   23.94 
Belite Bio Inc  23.14 
Artelo Biosciences Inc   22.20 
Disc Medicine Inc   22.15 
Diamedica Therapeutics Inc   21.10 
Savara Inc   21.02 
Minerva Neurosciences Inc   21.00 
Prometheus Biosciences Inc   20.91 
Kezar Life Sciences Inc   20.76 
Akero Therapeutics Inc   20.69 
Janux Therapeutics Inc   20.57 
Edgewise Therapeutics inc   20.54 
Pmv Pharmaceuticals Inc   20.33 
Nextcure Inc   20.32 
Kura Oncology Inc   19.97 
Lantern Pharma Inc   19.50 
Keros Therapeutics Inc   19.37 
Nuvalent Inc   19.19 
Stoke Therapeutics Inc   19.01 
Day One Biopharmaceuticals Inc   18.97 
Lixte Biotechnology Holdings Inc   18.41 
Viking Therapeutics Inc   18.05 
Agios Pharmaceuticals Inc   17.73 
Immuneering Corporation  17.57 
Cymabay Therapeutics Inc   17.53 
Zomedica Corp   17.50 
Cohbar Inc   17.47 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com